Comment and reply on: Pegfilgrastim is safe and effective in the prevention of neutropenia and treatment delays in biweekly regimens

Daniele SantiniUniversity Campus Bio-Medico, Department of Medical Oncology, Via Alvaro Del Portillo 200, 00128, Rome, Italy+0039 348 2574278; [email protected]

Anna Maria FrezzaUniversity Campus Bio-Medico, Department of Medical Oncology, Via Alvaro Del Portillo 200, 00128, Rome, Italy

Olga VendittiUniversity Campus Bio-Medico, Department of Medical Oncology, Via Alvaro Del Portillo 200, 00128, Rome, Italy

Salvatore IntagliataUniversity Campus Bio-Medico, Department of Medical Oncology, Via Alvaro Del Portillo 200, 00128, Rome, Italy

Emanuela dell'AquilaUniversity Campus Bio-Medico, Department of Medical Oncology, Via Alvaro Del Portillo 200, 00128, Rome, Italy

Francesco GuidaUniversity Campus Bio-Medico, Department of Medical Oncology, Via Alvaro Del Portillo 200, 00128, Rome, Italy

Bruno VincenziUniversity Campus Bio-Medico, Department of Medical Oncology, Via Alvaro Del Portillo 200, 00128, Rome, Italy

Giuseppe ToniniUniversity Campus Bio-Medico, Department of Medical Oncology, Via Alvaro Del Portillo 200, 00128, Rome, Italy

Nicola SilvestrisNational Cancer Research Centre ‘Giovanni Paolo II’, Medical Oncology Unit, Bari, [email protected]; National Cancer Research Centre ‘Giovanni Paolo II’, Medical Oncology Unit, Bari, Italy

Anna Elisabetta BrunettiNational Cancer Research Centre ‘Giovanni Paolo II’, Scientific Direction, Bari, Italy

Attilio GuariniNational Cancer Research Centre ‘Giovanni Paolo II’, Hematology Oncology Unit, Bari, Italy

Marzia Del ReUniversity of Pisa, Division of Pharmacology, Department of Internal Medicine, Pisa, Italy

Romano DanesiUniversity of Pisa, Division of Pharmacology, Department of Internal Medicine, Pisa, Italy

Saverio Cinieri‘Sen. Antonio Perrino’ Hospital, Medical Oncology Division and Breast Unit, Brindisi, Italy

show all

Bibliography

Yang BB, Kido A, Shibata A. Serum pegfilgrastim concentrations during recovery of absolute neutrophil count in patients with cancer receiving pegfilgrastim after chemotherapy. Pharmacotherapy 2007;27(10):1387-93
PubMed Web of Science ®Google Scholar
Dragnev KH, Hardin SB, Pipas JM, A dose escalation trial of biweekly docetaxel and gemcitabine with filgrastim or pegfilgrastim for the treatment of patients with advanced solid tumors. Chemotherapy 2010;56(2):135-41
PubMedGoogle Scholar
Mey UJ, Maier A, Schmidt-Wolf IG, Pegfilgrastim as hematopoietic support for dose-dense chemoimmunotherapy with R-CHOP-14 as first-line therapy in elderly patients with diffuse large B cell lymphoma. Support Care Cancer 2007;15:877-84
PubMed Web of Science ®Google Scholar
Piedbois P, Serin D, Priou F, Dose-dense adjuvant chemotherapy in node-positive breast cancer: docetaxel followed by epirubicin/cyclophosphamide (T/EC), or the reverse sequence (EC/T), every 2 weeks, versus docetaxel, epirubicin and cyclophosphamide (TEC) every 3 weeks. AERO B03 randomized phase II study. Ann Oncol 2007;18:52-7
PubMedGoogle Scholar

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Order Reprints Request Corporate Permissions

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

Request Academic Permissions

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.

Comment and reply on: Pegfilgrastim is safe and effective in the prevention of neutropenia and treatment delays in biweekly regimens

Bibliography

Information for

Open access

Opportunities

Help and information

Your download is now in progress and you may close this window

Login or register to access this feature

Comment and reply on: Pegfilgrastim is safe and effective in the prevention of neutropenia and treatment delays in biweekly regimens

Bibliography

Reprints and Corporate Permissions

Academic Permissions

Related research

To cite this article:

Download citation

Information for

Open access

Opportunities

Help and information

Keep up to date